Five Takeaways from the University of Maryland CERSI Pediatric Conference
Surprising takeaways from the recent University of Maryland CERSI workshop, Shaping the Future of Pediatric Formulation Development.
Explore expert perspectives, scientific advances, and practical strategies to help develop medicines that patients are willing to take.
Do you have an idea for a future topic? We’d like to hear from you at feedback@senopsys.com.
Surprising takeaways from the recent University of Maryland CERSI workshop, Shaping the Future of Pediatric Formulation Development.
Senopsys, a leader in developing palatable medicines through sensory science, today announced its 20th anniversary serving the global biopharmaceutical industry.
Taste, aroma, mouthfeel, texture, and aftertaste remain uniquely human—and uniquely measurable through validated sensory science methodologies developed over decades.
The increasing use of flavored, chewable, and rapidly dissolving dosage forms has transformed the patient experience of taking medicines—particularly for pediatric and geriatric populations. At the same time, these innovations have raised an important regulatory question: When does a medicine become “too much like candy”?
Senopsys and First Aid Shot Therapy (FAST) collaborated to improve the taste and consumption experience of common OTC products. This resulted in a series of great tasting, single dose liquid medicine shots that start working in minutes.
Senopsys and Bristol-Myers Squibb presented results of a process used to develop palatable pediatric chewable tablet formulations for two APIs with different taste masking challenges. Development followed a two-stage design: Stage 1 – Taste Assessment to quantify the taste masking challenge. Stage 2 – Taste Optimization following a sensory-directed formulation development approach. Click here to